TILS.L Share News (TILS)
TILS Share
TILS Share
TILS Share
TILS Share
TILS
TILS Share
TILS Broker
TILS Directors
TILS Financial
TILS
TILS Short
TILSMon, 03rd Dec 2018 11:51
LONDON (Alliance News) - Tiziana Life Sciences PLC on Monday said it completed patient enrollment in a Phase 2a trial of Milciclib in hepatocellular carcinoma.
The company explained that the study is a six-month trial to evaluate the tolerability and anti-tumor activity of its small molecule inhibitor, Milciclib, in liver cancer.
The company expects top line data from the trial in the second quarter of 2019.
Tiziana shares were trading up 6.3% at 67.50 pence each.
Tiziana Life Sciences has been granted an exclusive license to develop and commercialise Novimmune SA's CD3 receptor monoclonal antibody foralumab. Foralumab can be utilised for a range of autoimmune and inflammatory diseases, such multiple sclerosis, type-1 diabetes, inflammatory bowel disease, pso
Read more
